Table 3. Volume and cost of insulins by class-duration of action and molecular origin in Poland.
Number of DDDs in thousands. Costs in USD x 1000.
| Insulin type | 2012 | 2013 | 2014 | 2015 | |
|---|---|---|---|---|---|
| Biphasic/human | Volume; DDD (%) | 73,313 (36.43) | 78,975 (34.91) | 79,200 (33.1) | 76,950 (31.41) |
| Cost; USD (%) | 114,835 (32.19) | 122,291 (30.36) | 120,801 (28.54 | 117,125 (26.82) | |
| Biphasic/analogue | Volume; DDD (%) | 12,525 (6.22) | 13,200 (5,83) | 13,613 (5.69) | 13,125 (5.36) |
| Cost; USD (%) | 25,593 (7.17) | 26,743 (6.64) | 27,359 (6.44) | 26,389 (6.04) | |
| Short/human | Volume; DDD (%) | 23,325 (11.59) | 26,100 (11.54) | 21,038 (8.79) | 21,750 (8.88) |
| Cost; USD (%) | 36,451 (10.22) | 40,364 (10.02) | 41,448 (9.76) | 43,131 (9.88) | |
| Short/analogue | Volume; DDD (%) | 59,175 (29.40) | 67,650 (29.90) | 73,013 (30.51) | 76,800 (31.35 |
| Cost; USD (%) | 122,654 (34.39) | 138,715 (34.44) | 148,228 (34.91) | 155,659 (35.65) | |
| Long/human | Volume; DDD (%) | 30,375 (15.09) | 34,725 (15.35) | 44,100 (18.43) | 46,463 (18.97) |
| Cost; USD (%) | 47,576 (13.34) | 53,855 (13.37) | 56,251 (13.25) | 59,068 (13.53) | |
| Long/analogue | Volume; DDD (%) | 2,550 (1.27) | 5,588 (2.47) | 8,325 (3.48) | 9,900 (4.04) |
| Cost; USD (%) | 9,598 (2.69) | 20,851 (5.18) | 30,515 (7.19) | 35,273 (8.08) | |
| Total | Volume; DDD (%) | 201,263 (100.00) | 226,238 (100.00) | 239,288 (100.00) | 244,988 (100.00) |
| Cost; USD (%) | 356,707 (100) | 402,819 (100) | 424,599 (100) | 436,645 (100) | |
DDD: definded daily dose; USD: United States Dollar